Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$2.39 +0.19 (+8.64%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$2.24
$2.45
50-Day Range
$2.01
$2.74
52-Week Range
$1.20
$4.05
Volume
49,012 shs
Average Volume
78,491 shs
Market Capitalization
$26.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 732nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    CytoMed Therapeutics has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.47% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.47% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.
    Receive GDTC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    GDTC Stock News Headlines

    How Trade Wars Are Creating Fresh Opportunities for Investors
    Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”
    CytoMed Therapeutics Limited (GDTC)
    See More Headlines

    GDTC Stock Analysis - Frequently Asked Questions

    CytoMed Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, GDTC stock has decreased by 34.0% and is now trading at $2.2450.
    View the best growth stocks for 2025 here
    .

    CytoMed Therapeutics (GDTC) raised $10 million in an IPO on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share.

    Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

    Company Calendar

    Today
    5/27/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:GDTC
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $5.00
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $5.00
    Potential Upside/Downside
    +126.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $69,501.00
    Price / Cash Flow
    N/A
    Book Value
    $0.78 per share
    Price / Book
    2.83

    Miscellaneous

    Free Float
    N/A
    Market Cap
    $24.12 million
    Optionable
    Not Optionable
    Beta
    -0.31
    Free Today: Your Guide to Smarter Options Trades Cover

    Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

    Get This Free Report

    This page (NASDAQ:GDTC) was last updated on 5/27/2025 by MarketBeat.com Staff
    From Our Partners